Tempest Therapeutics has appointed Nicholas Rossettos as Chief Financial Officer, effective September 1, 2026, following Justin Trojanowski's resignation from the position. This Leadership shift reflects the company’s evolving financial strategy.
Key Highlights
- Nicholas Rossettos has been appointed CFO, Treasurer, and Corporate Secretary.
- Rossettos brings over 30 years of financial experience in biopharmaceutical and life sciences sectors.
- Tempest Therapeutics, Inc. (NASDAQ: TPST) will see a significant change in its financial leadership with the appointment of Nicholas Rossettos as Chief Financial Officer.
Tempest Therapeutics, Inc. (NASDAQ: TPST) will see a significant change in its financial leadership with the appointment of Nicholas Rossettos as Chief Financial Officer. Rossettos is set to take over the role effective September 1, 2026, following the resignation of Justin Trojanowski, who has held these key positions within the company. Trojanowski’s departure is part of an ongoing transition as the company aligns its financial leadership with its strategic goals.
Leadership Transition
Trojanowski notified Tempest Therapeutics of his intention to resign from all of his positions, which will take effect on September 1, 2026. The leadership change indicates a shift in the financial direction and governance of the organization, emphasizing a focus on innovative management in its financial operations.
Nicholas Rossettos Takes Charge
Nicholas Rossettos, appointed to Fill the role vacated by Trojanowski, comes with a Wealth of experience spanning over 30 years in corporate finance, particularly in the life sciences and biopharmaceutical sectors. The Board's decision to appoint him reflects a commitment to enhance financial oversight and strategic direction at the company.
Implications of the Appointment
The appointment of Rossettos suggests that Tempest Therapeutics is prioritizing experienced financial management capable of managing complex markets. His extensive history of consulting for growth-stage companies and serving as CFO for early-stage startups, like Egenix, Inc. showcases his readiness for this senior role within Tempest. This change may pave the way for enhanced financial strategies and operational efficiencies, likely aligning with the company’s future growth objectives.
What to Watch Next
Investors and Stakeholders should keep an eye on Tempest Therapeutics as it approaches the September 1, 2026, transition date for Rossettos. Future communications from the company will likely address how this leadership shift may impact corporate strategy and financial planning. Observing Rossettos’ early decisions and strategic directions will be important for understanding the company’s upcoming operational initiatives and financial health.
Peers Moving on This News
- BioVie Inc (NASDAQ: BIVI) down 6.1%
- Cyclerion Therapeutics Inc (NASDAQ: CYCN) up 2.8%



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...